Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2 (Hyper2)
Essential Hypertension, Metabolic Cardiovascular Syndrome, Heart Disease Risk Factors
About this trial
This is an interventional health services research trial for Essential Hypertension focused on measuring Remote telemonitoring, Uncontrolled hypertension, Artificial intelligent
Eligibility Criteria
Inclusion criteria: Primary arterial hypertension in drug treatment with at least 3 classes of antihypertensive drugs in optimized dose Aged between 20 and 65 years Blood pressure of the office ≥ 140 and/or 90 mmHg Facilities to use mobile and apps Exclusion criteria: Stroke sequelae Cognitive dysfunction
Sites / Locations
- Heart Institute (InCor), Hospital das Clinicas do HCFMUSP
Arms of the Study
Arm 1
Arm 2
Other
No Intervention
Avatr
Control
In the inclusion visit, it will be install the Avatr App in the mobile device of the patients. The patients will give an evaluation to perform by the medical and nursing staff, where clinical data (office blood pressure, weight, height, abdominal circumference) will be collected and will answer questionnaires on quality of life, anxiety, sleep quality, food intake and therapeutic adherence. They will receive an automatic blood pressure measurement device to make household blood pressure measurement according to nursing guidance. Also, the patients will collected blood samples to further analysis for biochemical profile and 24-hour urine collection sample for urinary sodium dosage. The patients will take four in person visits after the initial visit, with the final visit after 12 months.
The patients will perform the same initial evaluation and answer the same questionnaires as described above for the Intervention Group. In this evaluation they will receive guidance regarding the adoption of life habits by the multidisciplinary team. The Control Group will receive reinforcement of guidance only in face-to-face visits. The patients will take four in person visits after the initial visit, with the final visit after 12 months.